MeSH tree: D12.776.124.486.485.114.224
With yet a third new Alzheimer's drug expected to be approved by the Food and Drug Administration (FDA), the field is beginning to show progress in the fight to slow the disease.
Jul 17, 2023
0
82
A new research paper was published in Oncotarget, titled, "Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series."
Jul 14, 2023
0
48
For adults with rheumatoid arthritis (RA), there is a modest reduction in the mean Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP) at three months for patients receiving tofacitinib (TOF) versus adalimumab ...
Jul 13, 2023
0
53
Health insurers and medical providers are battling over who should supply high-cost infusion drugs for patients, with the tussle over profits now spilling into statehouses across the country.
Jul 13, 2023
0
32
Two drugs commonly used to treat inflammatory diseases such as rheumatoid arthritis and psoriasis did not shorten recovery time for patients hospitalized with severe COVID-19 but did reduce the likelihood of death when compared ...
Jul 10, 2023
0
41
The odds of contracting Lyme disease from tick bites during warmer weather months continue to rise. That's due to a series of factors, including changes in climate conducive to maintenance of tick populations over a longer ...
Jun 27, 2023
0
44
For patients with minimally active or inactive uveitis and persistent or recurrent uveitic macular edema (ME), dexamethasone is significantly better for treatment than methotrexate or ranibizumab, according to a study published ...
Jun 22, 2023
0
30
Hospitals participating in the 340B Drug Pricing Program, a large federal safety-net program, are financially incentivized to prescribe original biologic drugs to prevent and treat diseases in lieu of cheaper generic-like ...
Jun 21, 2023
0
65
For patients with refractory immune checkpoint inhibitor (ICI)-induced colitis, fecal microbiota transplantation (FMT) is an effective treatment, according to a study published in the June 14 issue of Science Translational ...
Jun 16, 2023
0
63
For patients with relapsing-remitting multiple sclerosis (MS), rituximab is not noninferior to ocrelizumab, according to a study published online June 12 in JAMA Neurology.
Jun 14, 2023
0
32
